Manitoba Buprenorphine/naloxone Recommended Practice Manual
CPSM convened a working group of experts in the treatment of opioid use disorder in the spring of 2019. This working group has been tasked with assisting CPSM staff in developing a new Recommended Practice Manual for the use of buprenorphine/naloxone in the context of Opioid Agonist Therapy in Manitoba. CPSM receives frequent requests for guidance on the issues the working group is discussing. The working group has thus elected to publish its recommendations, in the areas of care that generate the most frequent inquiries, below.
Physicians are encouraged to adopt and incorporate these recommendations into their Opioid Agonist Therapy practices without delay. Please note that once the work of the working group is concluded, the complete new manual will be made available online on the CPSM website. Should members have any questions about the interpretation of the guidance published in the documents below in the interim, please do not hesitate to contact the chair of the working group at CPSM, Dr. Marina Reinecke. It is the working group’s hope that you will find this guidance useful in providing care to your patients on buprenorphine/naloxone.
- Introduction: Application, Training, & Regulatory Requirements to Provide OAT
- Buprenorphine/naloxone Take-home (Carry) Dosing Recommendations
- Unwitnessed Induction Section
- In-Hospital Care Section
- Micro-dosing Guidance
- Sublocade: Considerations in Informed Consent & Resources
- HIV & Hepatitis C in the Patient with OUD - Prevention, Screening, & Management